AMERICAN ACADEMY OF NEUROLOGY for AMERICAN ACADEMY OF NEUROLOGY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2019 | $250,000 | Replaced |
| 2nd Quarter - Amendment | Jul 21, 2020 | $350,000 | Yes |
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Veterans VET
Strengthening the VA Centers of Excellence
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
Taxation/Internal Revenue Code TAX
H.R. 88; Section 505: Repeal of Unrelated Business Income Tax on Qualified Transportation Fringe Benefits
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
Health Issues HCR
S. 73: End Taxpayer Subsidies for Drug Ads Act; all provisions. S. 348/H.R. 1763: Support the Resident Physician Shortage Reduction Act of 2019; all provisions. S. 427 / H.R. 1058: Autism CARES Act of 2019; all provisions. S. 948/ H.R. 2895: Conrad State 30 and Physician Access Reauthorization Act; all provisions. S. 1384: Prescription Drug Rebate Reform Act of 2019; all provisions. S. 1391 / H.R. 2296: FAIR Accountability and Innovative Research Drug Pricing Act; all provisions. S. 3032: Cannabidiol and Marijuana Research Expansion Act; all provisions. H.R. 1155: Preventing Unkind and Painful Procedures and Experiments on Respected Species Act of 2019; all provisions. H.R. 2113: Prescription Drug STAR Act: Sections 2 and 5 H.R. 2279: Safe Step Act; all provisions. H.R. 3030: Patient-Centered Outcomes Research Extension Act of 2019; all provisions. H.R. 3439: Protecting Access to Information for Effective and Necessary Treatment (PATIENTS) Act of 2019; all provisions. Supporting policies to address prescription drug costs, including improving drug pricing transparency and eliminating or reducing direct-to-consumer advertising. Funding for the National Neurological Conditions Surveillance System and opposing certain expansions to this program. Research into firearm morbidity and mortality prevention at CDC, fetal tissue research, and the NIH including the BRAIN Initiative. Funding for Congressionally Directed Medical Research Programs at the DoD. Raising budget caps to avoid sequestration. Policy to address surprise medical billing. Promoting interoperability in electronic health records.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
| AMY KALOIDES | Legislative Aid, Sen. Mark Dayton. |
| MATTHEW ROSS KERSCHNER | — |
| NATALIE PONTZER | — |
Medicare/Medicaid MMM
S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act; all provisions. H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019; all provisions. H.R. 2282: Medicare Care Coordination Improvement Act of 2019; all provisions. H.R. 3107: Improving Seniors' Timely Access to Care Act of 2019; all provisions. Supporting policies to address prescription drug costs, including supporting direct negotiation in Medicare, improving drug pricing transparency, extending negotiated Rx discounts to be passed through to patients cost-sharing requirements, and capping beneficiary out-of-pocket costs in Medicare Part D. Issues associated with Qualified Clinical Data Registry implementation, measures, and interoperability. CMS proposed rule altering Evaluation and Management billing codes. Issues associated with defining a rehabilitation physician within the inpatient rehabilitation setting. Improvements to the Medicare Access and CHIP Reauthorization Act of 2015. Appropriate use criteria for imaging services. Medicare coverage of oxygen therapy for cluster headaches.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEREK CHRISTOPHER BRANDT | — |
| AMY KALOIDES | Legislative Aid, Sen. Mark Dayton. |
| MATTHEW ROSS KERSCHNER | — |
| NATALIE PONTZER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.